JonesTrading analyst Soumit Roy maintained a Buy rating on Cassava Sciences (SAVA – Research Report) on May 6 and set a price target of $100.00. The company's shares closed last Friday at $20.05, close to its 52-week low of $18.07. According to TipRanks.com, Roy is a 4-star analyst with an average return of 5.1% and a 29.8% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals. Currently, the analyst consensus on Cassava Sciences is a Moderate Buy with an average price target of $92.50, representing a 357.0% upside. In a report issued on May 5, H.C.
https://www.tipranks.com/news/blurbs/jonestrading-thinks-cassava-sciences-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Cassava Sciences Charts.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Cassava Sciences Charts.